Completed PHASE1 INTERVENTIONAL 2-arm NCT02233751

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

An Open-Label Study to Evaluate the Pharmacokinetics of Testosterone Enanthate After Single-Dose Injection Via QuickShot® Testosterone in Healthy Male Subjects

Sponsor: Antares Pharma Inc.

Conditions Hypogonadism

Interventions Testosterone enanthate auto-injector

Updated 10 times since 2017 Last updated: Jan 18, 2019 Started: Sep 30, 2014 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02233751, this PHASE1 trial focuses on Hypogonadism and remains completed. Sponsored by Antares Pharma Inc., it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Feb 2020 — Jan 2021 [monthly]

Completed PHASE1
May 2019 — Feb 2020 [monthly]

Completed PHASE1
Jun 2018 — May 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Antares Pharma Inc.

Data source: Antares Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States